TP53 and neoplasm: Indeed, albeit all the BRAFV600E-challenged ATIIs showed increased DNA damage, while non-transformed ATIIs express p21CIP1 in the absence of p53 activation, tumorigenic ATIIs displayed enhanced p53 expression coupled with a significant p21CIP1reduction compared to non-tumor cells.